Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Medicenna Therapeutics Corp ( (TSE:MDNA) ) is now available.
Medicenna Therapeutics Corp announced the results of its annual meeting of shareholders, where all nominees listed in the management information circular were elected as directors. Dr. John H. Sampson did not stand for re-election but will continue to support the company as a clinical advisor. This meeting underscores the company’s stable leadership and ongoing commitment to advancing its innovative immunotherapy pipeline, which could have significant implications for its market positioning and stakeholder interests.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.
To see Spark’s full report on TSE:MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, as well as first-in-class Empowered Superkines. Their products, such as MDNA11 and bizaxofusp, are designed to stimulate cancer-killing cells and have been granted FastTrack and Orphan Drug status by the FDA and EMA. The company is also working on early-stage programs like BiSKITs™ and T-MASK™ to enhance the treatment of immunologically ‘cold’ tumors.
Average Trading Volume: 35,768
Technical Sentiment Signal: Sell
Current Market Cap: C$65.98M
For an in-depth examination of MDNA stock, go to TipRanks’ Overview page.